Axial Vector Energy Corp. owns, develops, finances and licenses advanced next generation energy technologies that have tremendous potential in industrial and commercial energy-related applications around the world. The Axial Vector engine converts chemical energy from a variety of different fuels into motion, but much more efficiently than a standard engine.

In addition to the company’s revolutionary engine technologies, Axial Vector has designed a new family of high-power, high-efficiency ‘Axial Flux’ electric generators. In combination, Axial Vector’s engine is designed to be seamlessly integrated with two 100 kW Axial Flux generators in order to create a 200 kW generator set (GENSET) that is expected to become the company’s first commercially marketed product.

The commercial applications for the company’s engine and GENSETs are enormous. The Axial Vector engine has many advantages including: its smaller size and weight, fewer operating parts and lower maintenance, an

...

Cubist Pharmaceuticals, Inc. (CBST) reported a third-quarter net income of 65 cents per share, which was much higher than the Zacks Consensus Estimate of 33 cents. The company’s net income was 48 cents per share in the year-ago quarter. The higher profit in the quarter was primarily because of increased sales coming from all the segments. Revenues in the quarter increased 28% to $143.5 million. U.S. product revenues increased 26.1% to $137.66 million in the quarter. Cubist recorded international product revenues of $3.93 million as against $1.43 million last year. Service revenues came in at $1.50 million from $1.42 million, and other revenues increased to $0.45 million from $0.39 million. Research & Development (R&D) spend for the quarter increased 24.1% to $35.5 million. Sales & Marketing expenses for the quarter decreased 15% to $18.9 million. General & Administrative (G&A) spend increased to $12.8 million from $9.3 ...

Axial Vector Energy Corp. today reminded investors that that its revolutionary Axial Vector Engine will be featured on the Global News Group Program “Special Edition TV” on Sunday, September 27th at 11:00 am EST. Designed to provide a platform for companies and organizations to talk about and present their solutions, the program provides international exposure via customized news reports reaching industry leaders and people through various news and media outlets.

Earlier this year, Host and Managing Editor of “Special Edition TV,” Ileana Bravo interviewed representatives from AVEC at their first United States based live demonstration of the “axial flux” and GENSET technology power generating system. The footage from these interviews, demonstrations, and other sources was compiled to deliver Axial’s story.

Ms. Bravo commented, “The fact that this engine runs on bio-based oil as fuel is significant in several ways. Palm oils that are

...

Axial Vector Energy Corp. announced this morning that its revolutionary Axial Vector Engine will be featured on the Global News Group Program “Special Edition TV.” The program provides a platform for companies and organizations to discuss and present their solutions. Select companies are also given international exposure via customized news reports reaching industry leaders and people through various news and media outlets.

Last month, Host and Managing Editor of “Special Edition TV”, Ileana Bravo interviewed representatives from AVEC at their first United States-based live demonstration of the “axial flux” and GENSET technology power generating system. The video taken from these interviews, demonstrations, and other sources has been compiled to help deliver Axial Vector’s story.

Ms. Bravo commented, “The fact that this engine runs on bio-based oil as fuel is significant in several ways. Palm oils that are totally renewable fuel sources can be

...

Last week, Cornerstone Therapeutics Inc. (CRTX) reported second quarter earnings of 13 cents per share, which was well below the Zacks Consensus Estimate of 33 cents. Net revenues for the quarter came in at $25 million, which reflected a 78% increase over the prior-year quarter. The company reported earnings of 31 cents per share in the previous year quarter. Operating expenses increased significantly in the quarter primarily due to increases in the workforce -- an increase in legal and accounting costs, costs associated with the Chiesi transaction, FDA regulatory-related fees, product liability, insurance-related costs, new product launches and royalties on increased product sales. As a reminder, Cornerstone Therapeutics Inc. was established through the merger of Critical Therapeutics with Cornerstone Biopharma Holdings Inc. in the fourth quarter of 2008. The financial statements for periods prior to the merger reflect the historical results of Cornerstone BioPharma, not ...

On July 24, New York-based biopharmaceutical company Regeneron Pharmaceuticals Inc. (REGN) announced that its once-weekly injection Arcalyst (Rilonacept) received a positive response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). The drug is used for treating Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue.

CHMP has recommended that rilonacept, an interleukin-1 blocker, be granted marketing authorization under exceptional circumstances. Such authorizations are granted to products on which comprehensive data cannot be provided by the company, which may happen due to the the rarity of the condition. The agency also asked Regeneron to  provide new information, if available, pertaining to the drug every year for review.

The company submitted a Marketing Authorization Application (MAA) with the EMEA for Arcalyst for the treatment of CAPS in the European

...

The Cheshire based Alexion Pharma (ALXN) reported second quarter earnings better than our estimates on strong sales of Soliris. The company reported GAAP net income from operations of $16.8 million ($0.19 per share) for the quarter compared to $2.4 million ($0.03 per share) in the year-ago period. The net income would have been on the higher side, but for the $3.4 million charge associated with the exchange of convertible notes during the quarter.  Revenue from operations increased 55% year on year and 14% sequentially to $92.3 million. Alexion Pharma derives its revenue from the sale of its only marketed product Soliris. Total operating expenses increased 23% to $61million primarily due to the 30% rise in SG&A expenses. The increase in SG&A expenses reflects the increased costs associated with the expansion of operations related to the launch of Soliris. The 9% increase in R&D expenses is due to ...

Cornerstone Therapeutics Inc (CRTX), a North Carolina-based specialty pharma company, got into a definitive asset purchase agreement with biopharmaceutical company Oscient Pharmaceuticals Corp. (OSCI) on July13, 2009. Under the agreement, CRTX agreed to purchase the commercial rights of Factive (gemifloxacin mesylate) for $5 million in North America and some European countries from OSCI, which has filed for Chapter 11 bankruptcy protection. Subsequently, the bankruptcy court is expected to pass its verdict within the next two months. Factive is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (AECB).  Factive belongs to the fluoroquinolone class of antibiotics. It received FDA approval in May 2007 for the five-day treatment of CAP. Cornerstone Therapeutics currently promotes its products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone also ...

We are awaiting the FDA approval of pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL). Cell Therapeutics (CTIC) has requested for priority review, which if granted could lead to an approval decision by the end of 2009 or early 2010.

The FDA has not yet accepted the NDA submission, which we expect to be decided by the FDA in the next couple of months. Pixantrone is currently available in Europe on a named-patient basis.

The NDA submission is a major event for the company but still we doubt its ability to challenge the dominance of Biogen Idec's (BIIB) Rituxan in this field. Though Pixantrone belongs to a class of cancer medicines known anthracylines, its molecular structure is different.

In spite of the effectiveness of anthracyclines especially for the treatment of NHL and breast cancer, its usage is however limited, due to severe cardiac toxicity. Since the company

...

Alexion Pharma (ALXN) is looking for label expansion of its only marketed product Soliris. At present, Soliris is used for treating a chronic disease Paroxysmal Nocturnal Hemoglobinuria (PNH) where red blood cells are destroyed causing severe anemia and blood clots.In an attempt to expand the scope of Soliris for other diseases, ALXN is conducting trials for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS) and kidney transplant patients. Estimates put the aHUS market at $400 million to $550 million annually, while the kidney transplant market could be worth $250 million annually.aHUS is a rare disorder in which patients are deficient in normally occurring complement regulatory proteins, leading to chronic inflammation, hemolysis and blood clots, ultimately resulting in kidney failure. The case reports of the patients showed that Soliris reduced hemolysis and platelet consumption, as well as improved kidney function in ...